
    
      Twenty subjects with OCD will be enrolled in the study. Participants will complete baseline
      assessments of fear and avoidance. Participants will be randomly assigned to a single dose of
      propranolol 40mg or placebo, administered immediately after a fear reactivation procedure.
      Primary outcome assessment will be OCD symptoms and avoidance behavior in a behavioral
      avoidance task 2 weeks after the intervention
    
  